EMVision Medical Devices (ASX:EMV) said that its first responder proof-of-concept device was tested in aeromedical retrieval environment settings, in collaboration with the Royal Flying Doctor Service and the Australian Stroke Alliance, according to a Wednesday Australian bourse filing.
The RFDS staff received preliminary training in the operation of the device with scans completed under an existing ethics approval. The device withstood the physical stress, environmental conditions, and operational constraints related to aeromedical retrieval.
It submitted an ethics application for the RFDS staff to enroll and scan patients in a usability and workflow implementation study set for the coming weeks.
The study will look at the device's usability, reliability, functionality, workflow metrics, among other tests.
Product development activities are underway to transition from advanced prototype proof-of-concept devices to production-equivalent commercial devices.
Another ethics application is underway for the use of the EMVision first responder scans during acute suspected stroke cases attended by the Melbourne Mobile Stroke Unit.
Its shares rose 5% in recent trading on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.